Ticker LaunchIPO · GRCL
Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. (GRCL) priced its initial public offering on Jan 8, 2021 at $19.00 per share, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $6.23B. Cooley and Harneys advised the company and Davis Polk, AllBright and Zhong Lun advised the underwriters.
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer using its FasTCAR and TruUCAR platforms. FasTCAR enables next-day manufacturing of autologous products, led by GC012F in relapsed or refractory multiple myeloma, while TruUCAR derives T cells from non-HLA-matched healthy donors.
- Status
- IPO
- Ticker
- GRCL
- Exchange
- Nasdaq Global Select
- Priced
- Jan 8, 2021
- IPO price
- $19.00
- Market cap at IPO price
- $6.23B
- First filed
- Dec 18, 2020
- Underwriters' counsel
- Davis Polk, AllBright and Zhong Lun
- Sector
- Biotech & pharma
- Country / state
- China
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Dec 18, 2020
- Latest amendment Jan 7, 2021
- Final prospectus (424B4) Jan 8, 2021
- All filings on EDGAR CIK 1826492
Other Biotech & pharma IPOs in 2021
- Landos Biopharma, Inc.LABP · Feb 4, 2021 · $100M
- Faeth Therapeutics, Inc.SNSE · Feb 4, 2021 · $133M
- NewcelX Ltd.NLSP · Feb 1, 2021 · $20M
- Ortho Clinical Diagnostics Holdings plcOCDX · Jan 29, 2021 · $1.29B
- BGM Group Ltd.QLI · Jan 12, 2021 · $25M
- Cullinan Therapeutics, Inc.CGEM · Jan 11, 2021 · $249.9M